Comparative study of CEA and CA19-9 in esophageal, gastric and colon cancers individually and in combination (ROC curve analysis)
To determine the clinical serum levels of carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9), individually and in combination, for the diagnosis of 50 healthy subjects and 150 cases of esophageal, gastric, and colon cancers. The sensitivities of the two markers were compared indiv...
Saved in:
Published in | Cancer biology & medicine Vol. 10; no. 3; pp. 148 - 157 |
---|---|
Main Authors | , , , |
Format | Journal Article |
Language | English |
Published |
China
Department of Biochemistry, S.M.S. Medical College & Hospital, Jaipur 302004, India%Department of Radiotherapy and 0ncology, S.M.S. Medical College&Hospital, Jaipur 302004, India%Advanced Bioinformatics Centre, Birla Institute of Scientific Research, Jaipur 302004, India
01.09.2013
Chinese Anti-Cancer Association China Anti-Cancer Association |
Subjects | |
Online Access | Get full text |
ISSN | 2095-3941 2095-3941 |
DOI | 10.7497/j.issn.2095-3941.2013.03.005 |
Cover
Loading…
Abstract | To determine the clinical serum levels of carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9), individually and in combination, for the diagnosis of 50 healthy subjects and 150 cases of esophageal, gastric, and colon cancers.
The sensitivities of the two markers were compared individually and in combination, with specificity set at 100%. Receiver operating characteristic (ROC) curves were plotted.
Serum CEA levels were significantly higher in cancer patients than in the control group. The sensitivity of CEA was determined: in esophageal cancer, sensitivity=28%, negative predictive value (NPV)=61.72%, and AUC=0.742
(SE=0.05), with a significance level of P<0.0001; in gastric cancer, sensitivity=30%, NPV=58.82%, and AUC=0.734 (SE=0.05), with a significance level of P<0.0001; in colon cancer, sensitivity=74%, NPV=79.36%, and AUC=0.856
(SE=0.04), with a significance level of P<0.0001. The sensitivity of CA19-9 was also evaluated: in esophageal cancer, sensitivity=18%, NPV=54.94%, and AUC=0.573 (SE =0.05), with a significance level of P=0.2054. In gastric cancer, sensitivity=42%, NPV=63.29%, and AUC=0.679 (SE =0.05), with a significance level of P<0.0011. In colon cancer, sensitivity=26%, NPV=57.47%, and AUC=0.580 (SE =0.05), with a significance level of P=0.1670. The following were the sensitivities of CEA/CA19-9 combined: in esophageal cancer, sensitivity=42%, NPV=63.29%, SE=0.078 (95% CI: 0.0159-0.322); gastric cancer, sensitivity=58%, NPV=70.42%, SE=0.072 (95% CI: -0.0866-0.198); and colon cancer, sensitivity=72%, NPV=78.12%, SE=0.070 (95% CI: 0.137-0.415).
CEA exhibited the highest sensitivity for colon cancer, and CA19-9 exhibited the highest sensitivity for gastric cancer. Combined analysis indicated an increase in diagnostic sensitivity in esophageal and gastric cancer compared with that in colon cancer. |
---|---|
AbstractList | Objective:To determine the clinical serum levels of carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9), individually and in combination, for the diagnosis of 50 healthy subjects and 150 cases of esophageal, gastric, and colon cancers. Methods:The sensitivities of the two markers were compared individually and in combination, with specificity set at 100%. Receiver operating characteristic (ROC) curves were plotted. Results:Serum CEA levels were significantly higher in cancer patients than in the control group. The sensitivity of CEA was determined:in esophageal cancer, sensitivity=28%, negative predictive value (NPV)=61.72%, and AUC=0.742 (SE=0.05), with a significance level of P<0.0001;in gastric cancer, sensitivity=30%, NPV=58.82%, and AUC=0.734 (SE=0.05), with a significance level of P<0.0001;in colon cancer, sensitivity=74%, NPV=79.36%, and AUC=0.856 (SE=0.04), with a significance level of P<0.0001. The sensitivity of CA19-9 was also evaluated:in esophageal cancer, sensitivity=18%, NPV=54.94%, and AUC=0.573 (SE=0.05), with a significance level of P=0.2054. In gastric cancer, sensitivity=42%, NPV=63.29%, and AUC=0.679 (SE=0.05), with a significance level of P<0.0011. In colon cancer, sensitivity=26%, NPV=57.47%, and AUC=0.580 (SE=0.05), with a significance level of P=0.1670. The following were the sensitivities of CEA/CA19-9 combined:in esophageal cancer, sensitivity=42%, NPV=63.29%, SE=0.078 (95%CI:0.0159-0.322);gastric cancer, sensitivity=58%, NPV=70.42%, SE=0.072 (95%CI:-0.0866-0.198);and colon cancer, sensitivity=72%, NPV=78.12%, SE=0.070 (95%CI:0.137-0.415). Conclusion:CEA exhibited the highest sensitivity for colon cancer, and CA19-9 exhibited the highest sensitivity for gastric cancer. Combined analysis indicated an increase in diagnostic sensitivity in esophageal and gastric cancer compared with that in colon cancer. To determine the clinical serum levels of carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9), individually and in combination, for the diagnosis of 50 healthy subjects and 150 cases of esophageal, gastric, and colon cancers.OBJECTIVETo determine the clinical serum levels of carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9), individually and in combination, for the diagnosis of 50 healthy subjects and 150 cases of esophageal, gastric, and colon cancers.The sensitivities of the two markers were compared individually and in combination, with specificity set at 100%. Receiver operating characteristic (ROC) curves were plotted.METHODSThe sensitivities of the two markers were compared individually and in combination, with specificity set at 100%. Receiver operating characteristic (ROC) curves were plotted.Serum CEA levels were significantly higher in cancer patients than in the control group. The sensitivity of CEA was determined: in esophageal cancer, sensitivity=28%, negative predictive value (NPV)=61.72%, and AUC=0.742 (SE=0.05), with a significance level of P<0.0001; in gastric cancer, sensitivity=30%, NPV=58.82%, and AUC=0.734 (SE=0.05), with a significance level of P<0.0001; in colon cancer, sensitivity=74%, NPV=79.36%, and AUC=0.856 (SE=0.04), with a significance level of P<0.0001. The sensitivity of CA19-9 was also evaluated: in esophageal cancer, sensitivity=18%, NPV=54.94%, and AUC=0.573 (SE =0.05), with a significance level of P=0.2054. In gastric cancer, sensitivity=42%, NPV=63.29%, and AUC=0.679 (SE =0.05), with a significance level of P<0.0011. In colon cancer, sensitivity=26%, NPV=57.47%, and AUC=0.580 (SE =0.05), with a significance level of P=0.1670. The following were the sensitivities of CEA/CA19-9 combined: in esophageal cancer, sensitivity=42%, NPV=63.29%, SE=0.078 (95% CI: 0.0159-0.322); gastric cancer, sensitivity=58%, NPV=70.42%, SE=0.072 (95% CI: -0.0866-0.198); and colon cancer, sensitivity=72%, NPV=78.12%, SE=0.070 (95% CI: 0.137-0.415).RESULTSSerum CEA levels were significantly higher in cancer patients than in the control group. The sensitivity of CEA was determined: in esophageal cancer, sensitivity=28%, negative predictive value (NPV)=61.72%, and AUC=0.742 (SE=0.05), with a significance level of P<0.0001; in gastric cancer, sensitivity=30%, NPV=58.82%, and AUC=0.734 (SE=0.05), with a significance level of P<0.0001; in colon cancer, sensitivity=74%, NPV=79.36%, and AUC=0.856 (SE=0.04), with a significance level of P<0.0001. The sensitivity of CA19-9 was also evaluated: in esophageal cancer, sensitivity=18%, NPV=54.94%, and AUC=0.573 (SE =0.05), with a significance level of P=0.2054. In gastric cancer, sensitivity=42%, NPV=63.29%, and AUC=0.679 (SE =0.05), with a significance level of P<0.0011. In colon cancer, sensitivity=26%, NPV=57.47%, and AUC=0.580 (SE =0.05), with a significance level of P=0.1670. The following were the sensitivities of CEA/CA19-9 combined: in esophageal cancer, sensitivity=42%, NPV=63.29%, SE=0.078 (95% CI: 0.0159-0.322); gastric cancer, sensitivity=58%, NPV=70.42%, SE=0.072 (95% CI: -0.0866-0.198); and colon cancer, sensitivity=72%, NPV=78.12%, SE=0.070 (95% CI: 0.137-0.415).CEA exhibited the highest sensitivity for colon cancer, and CA19-9 exhibited the highest sensitivity for gastric cancer. Combined analysis indicated an increase in diagnostic sensitivity in esophageal and gastric cancer compared with that in colon cancer.CONCLUSIONCEA exhibited the highest sensitivity for colon cancer, and CA19-9 exhibited the highest sensitivity for gastric cancer. Combined analysis indicated an increase in diagnostic sensitivity in esophageal and gastric cancer compared with that in colon cancer. To determine the clinical serum levels of carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9), individually and in combination, for the diagnosis of 50 healthy subjects and 150 cases of esophageal, gastric, and colon cancers. The sensitivities of the two markers were compared individually and in combination, with specificity set at 100%. Receiver operating characteristic (ROC) curves were plotted. Serum CEA levels were significantly higher in cancer patients than in the control group. The sensitivity of CEA was determined: in esophageal cancer, sensitivity=28%, negative predictive value (NPV)=61.72%, and AUC=0.742 (SE=0.05), with a significance level of P<0.0001; in gastric cancer, sensitivity=30%, NPV=58.82%, and AUC=0.734 (SE=0.05), with a significance level of P<0.0001; in colon cancer, sensitivity=74%, NPV=79.36%, and AUC=0.856 (SE=0.04), with a significance level of P<0.0001. The sensitivity of CA19-9 was also evaluated: in esophageal cancer, sensitivity=18%, NPV=54.94%, and AUC=0.573 (SE =0.05), with a significance level of P=0.2054. In gastric cancer, sensitivity=42%, NPV=63.29%, and AUC=0.679 (SE =0.05), with a significance level of P<0.0011. In colon cancer, sensitivity=26%, NPV=57.47%, and AUC=0.580 (SE =0.05), with a significance level of P=0.1670. The following were the sensitivities of CEA/CA19-9 combined: in esophageal cancer, sensitivity=42%, NPV=63.29%, SE=0.078 (95% CI: 0.0159-0.322); gastric cancer, sensitivity=58%, NPV=70.42%, SE=0.072 (95% CI: -0.0866-0.198); and colon cancer, sensitivity=72%, NPV=78.12%, SE=0.070 (95% CI: 0.137-0.415). CEA exhibited the highest sensitivity for colon cancer, and CA19-9 exhibited the highest sensitivity for gastric cancer. Combined analysis indicated an increase in diagnostic sensitivity in esophageal and gastric cancer compared with that in colon cancer. |
Author | Sood, Sadhna Lalwani, Soniya Sharma, Rameshwaram Bagaria, Bhawna |
AuthorAffiliation | Department of Biochemistry, S.M.S. Medical College & Hospital, Jaipur 302004, India%Department of Radiotherapy and 0ncology, S.M.S. Medical College&Hospital, Jaipur 302004, India%Advanced Bioinformatics Centre, Birla Institute of Scientific Research, Jaipur 302004, India |
AuthorAffiliation_xml | – name: Department of Biochemistry, S.M.S. Medical College & Hospital, Jaipur 302004, India%Department of Radiotherapy and 0ncology, S.M.S. Medical College&Hospital, Jaipur 302004, India%Advanced Bioinformatics Centre, Birla Institute of Scientific Research, Jaipur 302004, India |
Author_xml | – sequence: 1 givenname: Bhawna surname: Bagaria fullname: Bagaria, Bhawna organization: Department of Biochemistry, S.M.S. Medical College & Hospital, Jaipur 302004, India – sequence: 2 givenname: Sadhna surname: Sood fullname: Sood, Sadhna organization: Department of Biochemistry, S.M.S. Medical College & Hospital, Jaipur 302004, India – sequence: 3 givenname: Rameshwaram surname: Sharma fullname: Sharma, Rameshwaram organization: Department of Radiotherapy and Oncology, S.M.S. Medical College & Hospital, Jaipur 302004, India – sequence: 4 givenname: Soniya surname: Lalwani fullname: Lalwani, Soniya organization: Advanced Bioinformatics Centre, Birla Institute of Scientific Research, Jaipur 302004, India |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/24379990$$D View this record in MEDLINE/PubMed |
BookMark | eNpVkVFrHCEQx6WkNOk1X6HsQx8S6F51dXf1pXAsaRsIBEr7LLPqbjw8veruhctbv3nNXRoSERxmxt__r_MenfjgDUKfCF62TLRf1kubkl9WWNQlFYzkiNAlzhvXb9DZc_7kRXyKzlNa47w4pw3j79BpxWgrhMBn6G8XNluIMNmdKdI0630RhqK7WhXgddGtiChFYX1hUtjewWjAfS5GSFO06tChggu-UOCViSk3aruzegbn9odyvqnCprc-C-S-i5-3XaHmmLXAg9snmy4_oLcDuGTOn84F-v3t6lf3o7y5_X7drW5KXXHCyp73rOZNSwETaI0yVAjN24GrXigiOGMNrxSAwKRtBtMQBhUIbZhmNYH84AW6PnJ1gLXcRruBuJcBrDwkQhwlxMkqZ2StheDDoHFNDVMGekJUS0U9tDXvm2HIrK9H1nbuN0Yr46cI7hX0dcXbOzmGnaS8wZThDLg8Au7BD-BHuQ5zzD-S5MP44JyS5nGwmGL8aPziSSyGP7NJk9zYpIxz4E2YkyRM4JZykd0u0MeXvp4N_Z83_QevgrLA |
ContentType | Journal Article |
Copyright | Copyright © Wanfang Data Co. Ltd. All Rights Reserved. 2013 Cancer Biology & Medicine 2013 Cancer Biology & Medicine |
Copyright_xml | – notice: Copyright © Wanfang Data Co. Ltd. All Rights Reserved. – notice: 2013 Cancer Biology & Medicine 2013 Cancer Biology & Medicine |
DBID | NPM 7X8 2B. 4A8 92I 93N PSX TCJ 5PM DOA |
DOI | 10.7497/j.issn.2095-3941.2013.03.005 |
DatabaseName | PubMed MEDLINE - Academic Wanfang Data Journals - Hong Kong WANFANG Data Centre Wanfang Data Journals 万方数据期刊 - 香港版 China Online Journals (COJ) China Online Journals (COJ) PubMed Central (Full Participant titles) Directory of Open Access Journals |
DatabaseTitle | PubMed MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic PubMed |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 2095-3941 |
EndPage | 157 |
ExternalDocumentID | oai_doaj_org_article_5d998ffd053e4ceab11c7395f758b6ff PMC3860340 zgzllc_e201303004 24379990 |
Genre | Journal Article |
GroupedDBID | -05 -0E -SE -S~ 5VR 8FE 8FH 92F 92I 92M 9D9 9DE AAKDD ABDBF ABKZE ABUWG ACUHS ADRAZ AFKRA AFUIB ALMA_UNASSIGNED_HOLDINGS BBNVY BENPR BHPHI BPHCQ BVBZV CAJEE CCEZO CCPQU CHBEP CIEJG DIK EBD EOJEC ESX GROUPED_DOAJ HCIFZ HYE JUIAU KQ8 LK8 M48 M7P MET NPM OBODZ OK1 PGMZT PHGZM PHGZT PIMPY PQGLB PQQKQ PROAC Q-- Q-4 RNS RPM RT5 S.. T8U TCJ TGQ U1F U1G U5E U5O WFFXF ~N8 7X8 2B. 4A8 93N FA0 PMFND PSX R-E 5PM PUEGO |
ID | FETCH-LOGICAL-d2814-b8b458673a01a7ece399d87f8cb9c19844682caa90176fe614a2a9de4d451a243 |
IEDL.DBID | M48 |
ISSN | 2095-3941 |
IngestDate | Wed Aug 27 01:31:22 EDT 2025 Thu Aug 21 14:04:51 EDT 2025 Thu May 29 04:01:23 EDT 2025 Fri Jul 11 12:08:29 EDT 2025 Mon Jul 21 06:01:43 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 3 |
Keywords | Carcinoembryonic antigen Receiver operating characteristic curve carbohydrate antigen 19-9, human sensitivity and specificity carbohydrate antigen 19-9,human |
Language | English |
License | This work is licensed under a Creative Commons Attribution 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by/3.0 |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-d2814-b8b458673a01a7ece399d87f8cb9c19844682caa90176fe614a2a9de4d451a243 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Correspondence to: Bhawna Bagaria E-mail: bhawna_bagaria@yahoo.com |
OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.7497/j.issn.2095-3941.2013.03.005 |
PMID | 24379990 |
PQID | 1490738905 |
PQPubID | 23479 |
PageCount | 10 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_5d998ffd053e4ceab11c7395f758b6ff pubmedcentral_primary_oai_pubmedcentral_nih_gov_3860340 wanfang_journals_zgzllc_e201303004 proquest_miscellaneous_1490738905 pubmed_primary_24379990 |
PublicationCentury | 2000 |
PublicationDate | 2013-09-00 |
PublicationDateYYYYMMDD | 2013-09-01 |
PublicationDate_xml | – month: 09 year: 2013 text: 2013-09-00 |
PublicationDecade | 2010 |
PublicationPlace | China |
PublicationPlace_xml | – name: China |
PublicationTitle | Cancer biology & medicine |
PublicationTitleAlternate | Cancer Biol Med |
PublicationTitle_FL | Cancer Biology & Medicine |
PublicationYear | 2013 |
Publisher | Department of Biochemistry, S.M.S. Medical College & Hospital, Jaipur 302004, India%Department of Radiotherapy and 0ncology, S.M.S. Medical College&Hospital, Jaipur 302004, India%Advanced Bioinformatics Centre, Birla Institute of Scientific Research, Jaipur 302004, India Chinese Anti-Cancer Association China Anti-Cancer Association |
Publisher_xml | – name: Department of Biochemistry, S.M.S. Medical College & Hospital, Jaipur 302004, India%Department of Radiotherapy and 0ncology, S.M.S. Medical College&Hospital, Jaipur 302004, India%Advanced Bioinformatics Centre, Birla Institute of Scientific Research, Jaipur 302004, India – name: Chinese Anti-Cancer Association – name: China Anti-Cancer Association |
References | 22387886 - Eur J Gastroenterol Hepatol. 2012 Jun;24(6):605-12 11154168 - J Clin Gastroenterol. 2001 Jan;32(1):41-4 11984734 - Gastric Cancer. 2000 Dec;3(4):177-186 11957811 - Pol Merkur Lekarski. 2002 Jan;12(67):77-80 19413512 - Annu Rev Biomed Eng. 2009;11:177-202 18942720 - J Surg Oncol. 2009 Jan 1;99(1):65-70 19579599 - Hepatogastroenterology. 2009 Mar-Apr;56(90):361-6 21332006 - Turk J Gastroenterol. 2010 Dec;21(4):461-3 18439085 - Asian Pac J Cancer Prev. 2008 Jan-Mar;9(1):97-100 12237895 - Int J Cancer. 2002 Oct 20;101(6):545-8 19688060 - Cancer Res Treat. 2008 Mar;40(1):16-21 16033052 - Anticancer Res. 2005 May-Jun;25(3A):1507-15 16100946 - Cancer Invest. 2005;23(4):338-51 22810477 - Dis Colon Rectum. 2012 Aug;55(8):900-6 18821070 - Adv Ther. 2008 Oct;25(10):1075-84 15627885 - Tumour Biol. 2004 Sep-Dec;25(5-6):228-34 15383868 - World J Surg. 2004 Jul;28(7):680-5 8903494 - Eur J Surg Oncol. 1996 Oct;22(5):505-7 18375392 - J Biol Chem. 2008 Jun 6;283(23):15647-55 20396541 - Cancer Res Treat. 2004 Jun;36(3):178-81 12118264 - Rev Hosp Clin Fac Med Sao Paulo. 2002 May-Jun;57(3):89-92 10678558 - Jpn J Clin Oncol. 1999 Nov;29(11):550-5 8472349 - Clin Chem. 1993 Apr;39(4):561-77 14575569 - Zhonghua Zhong Liu Za Zhi. 2003 Sep;25(5):457-60 1603581 - Orv Hetil. 1992 May 24;133(21):1301-4, 1307 11274010 - Clin Chem. 2001 Apr;47(4):624-30 15362797 - Hepatogastroenterology. 2004 Sep-Oct;51(59):1544-7 2369087 - Anticancer Res. 1990 May-Jun;10(3):703-8 8869281 - J Pathol. 1996 Aug;179(4):358-69 11819806 - World J Gastroenterol. 2001 Jun;7(3):431-4 14520526 - Gastric Cancer. 2003;6(3):142-5 7690061 - Int J Biol Markers. 1993 Apr-Jun;8(2):88-93 14605576 - Dis Colon Rectum. 2003 Nov;46(11):1538-44 |
References_xml | – reference: 12237895 - Int J Cancer. 2002 Oct 20;101(6):545-8 – reference: 21332006 - Turk J Gastroenterol. 2010 Dec;21(4):461-3 – reference: 11819806 - World J Gastroenterol. 2001 Jun;7(3):431-4 – reference: 16100946 - Cancer Invest. 2005;23(4):338-51 – reference: 12118264 - Rev Hosp Clin Fac Med Sao Paulo. 2002 May-Jun;57(3):89-92 – reference: 2369087 - Anticancer Res. 1990 May-Jun;10(3):703-8 – reference: 11984734 - Gastric Cancer. 2000 Dec;3(4):177-186 – reference: 18821070 - Adv Ther. 2008 Oct;25(10):1075-84 – reference: 22387886 - Eur J Gastroenterol Hepatol. 2012 Jun;24(6):605-12 – reference: 14605576 - Dis Colon Rectum. 2003 Nov;46(11):1538-44 – reference: 8903494 - Eur J Surg Oncol. 1996 Oct;22(5):505-7 – reference: 16033052 - Anticancer Res. 2005 May-Jun;25(3A):1507-15 – reference: 19579599 - Hepatogastroenterology. 2009 Mar-Apr;56(90):361-6 – reference: 1603581 - Orv Hetil. 1992 May 24;133(21):1301-4, 1307 – reference: 11154168 - J Clin Gastroenterol. 2001 Jan;32(1):41-4 – reference: 20396541 - Cancer Res Treat. 2004 Jun;36(3):178-81 – reference: 15362797 - Hepatogastroenterology. 2004 Sep-Oct;51(59):1544-7 – reference: 19688060 - Cancer Res Treat. 2008 Mar;40(1):16-21 – reference: 11274010 - Clin Chem. 2001 Apr;47(4):624-30 – reference: 15383868 - World J Surg. 2004 Jul;28(7):680-5 – reference: 8869281 - J Pathol. 1996 Aug;179(4):358-69 – reference: 7690061 - Int J Biol Markers. 1993 Apr-Jun;8(2):88-93 – reference: 8472349 - Clin Chem. 1993 Apr;39(4):561-77 – reference: 14520526 - Gastric Cancer. 2003;6(3):142-5 – reference: 11957811 - Pol Merkur Lekarski. 2002 Jan;12(67):77-80 – reference: 18375392 - J Biol Chem. 2008 Jun 6;283(23):15647-55 – reference: 19413512 - Annu Rev Biomed Eng. 2009;11:177-202 – reference: 10678558 - Jpn J Clin Oncol. 1999 Nov;29(11):550-5 – reference: 22810477 - Dis Colon Rectum. 2012 Aug;55(8):900-6 – reference: 15627885 - Tumour Biol. 2004 Sep-Dec;25(5-6):228-34 – reference: 14575569 - Zhonghua Zhong Liu Za Zhi. 2003 Sep;25(5):457-60 – reference: 18439085 - Asian Pac J Cancer Prev. 2008 Jan-Mar;9(1):97-100 – reference: 18942720 - J Surg Oncol. 2009 Jan 1;99(1):65-70 |
SSID | ssj0000883648 |
Score | 2.2980475 |
Snippet | To determine the clinical serum levels of carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9), individually and in combination, for the... Objective:To determine the clinical serum levels of carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9), individually and in combination, for... |
SourceID | doaj pubmedcentral wanfang proquest pubmed |
SourceType | Open Website Open Access Repository Aggregation Database Index Database |
StartPage | 148 |
SubjectTerms | carbohydrate antigen 19-9, human Carcinoembryonic antigen Original Receiver operating characteristic curve sensitivity and specificity |
SummonAdditionalLinks | – databaseName: Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3daxQxEA9SaPFF6vdVK1H6oODazeb78VxailAFsdC3JZ_nyZErdz2KffM_d5JdzzsUfPF1Z0N285tMZpjJbxA6qp3wRtSy0oLpiglKKltHUjVUmkAlJTTk28jnH8XZBftwyS83Wn3lmrCeHrhfuGPuISCI0YOyBOaCsYS4nFyK4OhaEWO2vnDmbQRTxQYrRUVpnQVCXlHNyB46AgshmZbH38oGe7cW5Qov2nOd8oG7_28O5591k7s3JkWTJhtH0uk-ujf4knjc_8N9dCekB2jvfMiWP0Q_2t_U3rjwyOJ5xO3JGJvkcTsmutJ4mnDIrQzArpjZWzwxuZGHK29kQuuEXdaLxRJP11e3Zt-LGEaCukJkXcDFrz9_arFbLWAuMzCdvHmELk5PvrRn1dByofKNIqyyyjKuhKSmJkYGF8B_8UpG5ax2RCsIHlXjjAEvQooY4Gw3jdE-MM84MQ2jj9FOmqfwFOHIZaauN6yOigUhdc4ZcqEbp7yy1I7Q-7zQ3VXPqtFlnuvyANDvBvS7f6E_Qi9_wdTBvsjJDpPCfLWEkAbCfvDGaj5CT3rY1lMVEkY4hkdIbgG69S3bkjT9Wri3qRI1ZTDy1QB9N-z5ZXc7uZ3NXBeyMtWZyOzgf_zhM3S3KR04clnbc7RzvViFQ_CDru2LovI_AaIGA6M priority: 102 providerName: Directory of Open Access Journals |
Title | Comparative study of CEA and CA19-9 in esophageal, gastric and colon cancers individually and in combination (ROC curve analysis) |
URI | https://www.ncbi.nlm.nih.gov/pubmed/24379990 https://www.proquest.com/docview/1490738905 https://d.wanfangdata.com.cn/periodical/zgzllc-e201303004 https://pubmed.ncbi.nlm.nih.gov/PMC3860340 https://doaj.org/article/5d998ffd053e4ceab11c7395f758b6ff |
Volume | 10 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLbGJqa9IO6US2XQHkAiWxw7vjyhNrSakDrQRKW9RY5jl6IoHekq2N745xw7aaFiD4inSElsRz4Xny_H_g5Ch7HhpeaxiBRnKmKckqiIHYkSKrSlghJq_WnkySk_mbIP5-n5Dlpva-4mcHkjtPP1pKZNdfTj29U7MHiIX48EU-L4a7AXwHoqjahiHvUR2lKXprfQHqxRwhd1mHSBf_DRUlIeSmttWu2jw3_p0LMHew6_1ov7LWw3xaZ_b7G8_V3XTtezP1av8V10pws78aDVk3tox9b30f6kS6w_QD-z3yzgOFDO4oXD2WiAdV3ibEBUpPC8xtZXPQAXpKu3eKZ9zQ8T3vDc1zU2XoWaJZ5vTnlVV-ExtATNBhAe9AC_PvuYYbNqYCzdkaK8eYim49Hn7CTqqjNEZSIJiwpZsFRyQXVMtLDGQqhTSuGkKZQhSgLOlInRGgIOwZ2FMEAnWpWWlSwlGubwEdqtF7V9grBLhWe51yx2klkulE8vplwlRpayoEUPDf1E5xctAUfuKbHDjUUzyzsLy9MSkKNzJXgVy4zVBSHGZyEdIKKCO9dDL9diysGEfF5E13axWgL6UeDopIrTHnrcim0z1FrWPSS2BLr1LdtP6vmXQNNNJY8pg5avOtHna-3Or2fXVWVy6_Uq9pxnT_-7-2foIAkVOvy2t-do97JZ2RcQJ10WfbQ3GL4fjuE6HJ1-OuuH_w39YAi_AB3CEYE |
linkProvider | Scholars Portal |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Comparative+study+of+CEA+and+CA19-9+in+esophageal%2C+gastric+and+colon+cancers+individually+and+in+combination+%28ROC+curve+analysis%29&rft.jtitle=Cancer+biology+%26+medicine&rft.au=Bagaria%2C+Bhawna&rft.au=Sood%2C+Sadhna&rft.au=Sharma%2C+Rameshwaram&rft.au=Lalwani%2C+Soniya&rft.date=2013-09-01&rft.pub=Chinese+Anti-Cancer+Association&rft.issn=2095-3941&rft.volume=10&rft.issue=3&rft.spage=148&rft.epage=157&rft_id=info:doi/10.7497%2Fj.issn.2095-3941.2013.03.005&rft_id=info%3Apmid%2F24379990&rft.externalDocID=PMC3860340 |
thumbnail_s | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=http%3A%2F%2Fwww.wanfangdata.com.cn%2Fimages%2FPeriodicalImages%2Fzgzllc-e%2Fzgzllc-e.jpg |